JCHOR
Journal of Current Hematology & Oncology Research

The Journal of Current Hematology & Oncology Research regularly publishes internationally qualified research in hematology and oncology within the current scholarly knowledge. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

ISSN: Active
eISSN: 2980-0854
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index

Current Issue 2024/2/4

Original Article
Shedding light on allogeneic hematopoietic stem cell transplantation success: exploring the relationship between donor vitamin D and parathormone levels and recipient engraftment and stem cell quantity

Published: 14 Nov 2024

https://doi.org/10.51271/JCHOR-0044

Citation: Uzun D, Keklik M, Eser B. Shedding light on allogeneic hematopoietic stem cell transplantation success: exploring the relationship between donor vitamin D and parathormone levels and recipient engraftment and stem cell quantity . J Curr Hematol Oncol Res. 2024;2(4):79-82.

Original Article
Myeloid differentiation primary response 88 expression in central nervous system lymphomas

Published: 14 Nov 2024

https://doi.org/10.51271/JCHOR-0045

Citation: Balık B, Mutlu YG, Sevindik ÖG. Myeloid differentiation primary response 88 expression in central nervous system lymphomas. J Curr Hematol Oncol Res. 2024;2(4):83-86.

Original Article
Diagnostic white blood cells can be a predictor for mutation existence in myelodisplastic syndromes: the role of next generation sequencing

Published: 14 Nov 2024

https://doi.org/10.51271/JCHOR-0046

Citation: Yılmaz S, Günay A, Cırık S, Baştürk A, Başdemirci M, Balasar Ö. Diagnostic white blood cells can be a predictor for mutation existence in myelodisplastic syndromes: the role of next generation sequencing. J Curr Hematol Oncol Res. 2024;2(4):87-92.

Case Report
Can bispecific antibody therapies for multiple myeloma be a risk factor for the development of secondary haemotopoietic malignancy? A case report

Published: 14 Nov 2024

https://doi.org/10.51271/JCHOR-0047

Citation: Tan T, Doğan ÖD, Civriz Bozdağ S. Can bispecific antibody therapies for multiple myeloma be a risk factor for the development of secondary haemotopoietic malignancy? A case report. J Curr Hematol Oncol Res. 2024; 2(4): 93-94.

Case Report
Kikuchi-Fujimoto disease: a rare cause of fever and lymphadenopathy in a 19-year-old male

Published: 14 Nov 2024

https://doi.org/10.51271/JCHOR-0048

Citation: Çiftciler R, Çiftciler AE, Selim C, Çelik M. Kikuchi-Fujimoto disease: a rare cause of fever and lymphadenopathy in a 19-year-old male . J Curr Hematol Oncol Res. 2024;2(4): 95-97.

Case Report
A rare case of olfactory neuroblastoma

Published: 14 Nov 2024

https://doi.org/10.51271/JCHOR-0049

Citation: Karatlı S, Kavak EE. A rare case of olfactory neuroblastoma. J Curr Hematol Oncol Res. 2024;2(4):98-99.

Letter to the Editor
A comment on ‘The relationship between hepatocellular carcinoma and resolvin D1’ by Erdin et al.

Published: 14 Nov 2024

https://doi.org/10.51271/JCHOR-0050

Citation: Güven İE. The relationship between hepatocellular carcinoma and resolvin D1. J Curr Hematol Oncol Res. 2024;2(4):100.

Most Read Articles

Original Article
ß-catenin expression in myelodysplastic syndromes and myeloproliferative neoplasms in bone marrow, in relation to CD34 and CD117 status

Published: 30 Aug 2023

https://doi.org/10.51271/JCHOR-0013

Citation: Barış Iİ, Büyükbayram H. ß-catenin expression in myelodysplastic syndromes and myeloproliferative neoplasms in bone marrow, in relation to CD34 and CD117 status. J Curr Hematol Oncol Res. 2023;1(3):54-58.

Review
Chronic lymphocytic leukemia

Published: 30 Aug 2023

https://doi.org/10.51271/JCHOR-0014

Citation: Fidan K. Chronic lymphocytic leukemia. J Curr Hematol Oncol Res. 2023;1(3):59-67.

Original Article
Effect of tyrosine kinase inhibitor and conventional chemotherapy on COVID 19 antibody level in hematological patients

Published: 26 Feb 2023

https://doi.org/10.51271/JCHOR-0001

Citation: Kaya A, Berber İ, Kuku İ, et al. Effect of tyrosine kinase inhibitor and conventional chemotherapy on COVID-19 antibody level in hematological patients. J Curr Hematol Oncol Res. 2023; 1(1): 1-4

_Footer